---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-015114"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:25:40.799929+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Longeveron appoints Wa'el Hashad as CEO effective March 1, 2023

## Summary
- Wa'el Hashad named CEO, effective March 1, 2023; joins Board of Directors.
- Hashad previously President & CEO of Avanir Pharmaceuticals (2017-2023).
- Interim CEO Chris Min, M.D., Ph.D., returns to role as Chief Medical Officer.
- Compensation: $530k annual salary, up to 70% bonus, 50,000 RSU signing bonus.
- Hashad brings 35+ years experience at Amgen, Boehringer Ingelheim, Eli Lilly.

## SEC filing metadata
- accession: 0001213900-23-015114
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/0001213900-23-015114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/ea174406-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-015114
- JSON: https://secwatch.observer/filing/0001213900-23-015114.json
- Plain text: https://secwatch.observer/filing/0001213900-23-015114.txt

## Key facts
- Executive change
  Wa'el Hashad was appointed as Chief Executive Officer at Longeveron Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On February 22, 2023, the Board of Directors of Longeveron Inc. (the “Company”) appointed Mr. Wa’el Hashad to serve as the Company’s Chief Executive Officer, effective March 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/0001213900-23-015114-index.htm
- Executive change
  Chris Min changed role as Chief Medical Officer at Longeveron Inc..
  - Action: will continue to serve as Chief Medical Officer
  - Role: Chief Medical Officer
  source text: Dr. Chris Min, who has been serving as interim Chief Executive Officer, will continue to serve as Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/0001213900-23-015114-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.